Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a study titled ‘A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy.’ The study aims to assess the safety and efficacy of LY3848575 compared to a placebo in treating nerve pain that starts in the feet and progresses up the leg.
The intervention involves administering LY3848575 subcutaneously in low, mid, and high doses, alongside a placebo group, to determine the optimal dose for managing neuropathic pain.
This Phase 2 study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Its primary purpose is treatment-focused, ensuring unbiased results through participant and investigator masking.
The study began on August 22, 2024, with its latest update on June 24, 2025. These dates are crucial for tracking progress and ensuring transparency in the study’s development.
For investors, this study could influence Eli Lilly’s stock performance, as positive outcomes may enhance market confidence and competitive positioning in the neuropathic pain treatment sector.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.